Nanjing Vcare Shines at the 91st PHARMCHINA: One-stop CRDMO Services Attract Wide Attention

2025-11-25

　　The 91st National Pharmaceutical Fair (PHARMCHINA) & 2025 China International Health Nutrition Expo were held at Nanjing International Expo Center from November 19 to 21. Covering an exhibition area of 100,000 square meters, this event gathered more than 2,000 high-quality enterprises in the pharmaceutical and big health sectors at home and abroad, fully covering the entire pharmaceutical industrial chain. It serves as an important platform for participating enterprises to launch new products, exchange technologies and facilitate business cooperation.

 

 

　　As a key local pharmaceutical enterprise in Nanjing, Nanjing Vcare PharmaTech Co., Ltd. (Nanjing Vcare) set up a dedicated booth in the core exhibition area to fully showcase its R&D and innovation strengths. At Nanjing Vcare’s booth, the one-stop CRDMO service model clearly demonstrated its full-spectrum capabilities spanning early-stage drug research to commercial production. Such capabilities have been fully validated by the market. Up to now, Nanjing Vcare has provided professional services for over 300 domestic and international pharmaceutical enterprises, assisted clients in obtaining more than 50 marketing approvals for generic drugs and over 30 clinical trial approvals for innovative drugs, with over 80 projects currently under registration and application.

 

　　Meanwhile, Nanjing Vcare can stably supply more than 3,000 types of supporting intermediates, impurities and APIs, forming a rich and reliable product portfolio. This enables customers to achieve cost control and supply chain security throughout the R&D and production stages, and provides strong backend support for their products to enter national centralized procurement and medical insurance negotiations with competitive edges.

 

　　Participating in the exhibition in its hometown not only presents a concentrated display of Nanjing Vcare’s technological prowess, but also creates a vital opportunity to deepen cooperation with pharmaceutical peers worldwide and jointly build the industrial ecosystem. During the exhibition, multiple domestic and overseas pharmaceutical companies expressed intentions for cooperation, and in-depth negotiations on specific projects will be carried out in the follow-up phase.

Prev

Nanjing Vcare Selected as a Record-filing Entity for Jiangsu Provincial Enterprise Intellectual Property Standard Implementation

Next

Nanjing Vcare Debuts at the 93rd API China with One-stop CRO/CDMO Service Platform